Trial Profile
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Enoblituzumab (Primary) ; Pembrolizumab (Primary) ; Retifanlimab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cancer; Colon cancer; Head and neck cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pelvic cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Squamous cell cancer; Thyroid cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- Sponsors MacroGenics
- 03 May 2022 According to a MacroGenics media release, updated results were published in the Journal for ImmunoTherapy of Cancer in April (data cut-off: March 14, 2019).
- 22 Sep 2021 Status changed from active, no longer recruiting to completed.
- 13 Apr 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.